Visen
Ascendis Pharma (ASND) on Wednesday said it had submitted a new drug application to the U.S. FDA for its investigational drug TransCon PTH, which helps patients with hypoparathyroidism. $Ascendis制药(ASND)$
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
Visen
Ascendis Pharma (ASND) on Wednesday said it had submitted a new drug application to the U.S. FDA for its investigational drug TransCon PTH, which helps patients with hypoparathyroidism. $Ascendis制药(ASND)$